CA3121722C - Compose pyrimidine ou sel correspondant - Google Patents

Compose pyrimidine ou sel correspondant Download PDF

Info

Publication number
CA3121722C
CA3121722C CA3121722A CA3121722A CA3121722C CA 3121722 C CA3121722 C CA 3121722C CA 3121722 A CA3121722 A CA 3121722A CA 3121722 A CA3121722 A CA 3121722A CA 3121722 C CA3121722 C CA 3121722C
Authority
CA
Canada
Prior art keywords
group
compound
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3121722A
Other languages
English (en)
Other versions
CA3121722A1 (fr
Inventor
Masayuki Nakamura
Takahiro Asai
Satoru Iguchi
Kei OGUCHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CA3121722A1 publication Critical patent/CA3121722A1/fr
Application granted granted Critical
Publication of CA3121722C publication Critical patent/CA3121722C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Il est décrit un nouveau composé de pyrimidine ou un sel correspondant qui inhibe l'activité de HER2 et présente des propriétés de migration vers le cerveau, ainsi qu'une composition pharmaceutique le comprenant. Il est décrit un composé représenté par la formule générale (I) suivante ou un sel correspondant, de même que son utilisation dans le traitement d'une tumeur. (Dans la formule : R1 représente un groupe alkyle en C1-C4 qui peut comprendre un groupe alcoxy en C1-C4 en tant que substituant, ou un groupe cycloalkyle en C3-C4; R2 représente un atome d'hydrogène, un atome d'halogène, un groupe alkyle en C1-C6 qui peut comprendre, en tant qu'au moins un substituant, un maximum de cinq substituants choisis parmi les groupes alcoxy en C1-C4 et l'atome de fluor, ou un groupe alcoxy en C1-C6; R3 représente un atome d'hydrogène ou un groupe alkyle en C1-C4 qui peut comprendre, en tant qu'au moins un substituant, un maximum de cinq atomes de fluor; R4 représente un atome d'hydrogène ou un groupe alkyle en C1-C4; et R5 représente un groupe phényle qui peut comprendre un maximum de trois substituants choisis entre des atomes de fluor et des atomes de chlore.)
CA3121722A 2019-01-11 2020-01-10 Compose pyrimidine ou sel correspondant Active CA3121722C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019003403 2019-01-11
JP2019-003403 2019-01-11
PCT/JP2020/000592 WO2020145374A1 (fr) 2019-01-11 2020-01-10 Composé pyrimidine ou sel correspondant

Publications (2)

Publication Number Publication Date
CA3121722A1 CA3121722A1 (fr) 2020-07-16
CA3121722C true CA3121722C (fr) 2024-01-16

Family

ID=71520288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3121722A Active CA3121722C (fr) 2019-01-11 2020-01-10 Compose pyrimidine ou sel correspondant

Country Status (18)

Country Link
US (1) US11078207B2 (fr)
EP (1) EP3909584B1 (fr)
JP (1) JP6783974B1 (fr)
KR (1) KR102640463B1 (fr)
CN (1) CN113271950B (fr)
AU (1) AU2020206640B2 (fr)
BR (1) BR112021013460A2 (fr)
CA (1) CA3121722C (fr)
DK (1) DK3909584T3 (fr)
ES (1) ES2969151T3 (fr)
FI (1) FI3909584T3 (fr)
MA (1) MA54702A (fr)
MX (1) MX2021008252A (fr)
PL (1) PL3909584T3 (fr)
PT (1) PT3909584T (fr)
SG (1) SG11202107528PA (fr)
TW (1) TWI783204B (fr)
WO (1) WO2020145374A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023000765A2 (pt) * 2020-07-15 2023-02-07 Taiho Pharmaceutical Co Ltd Cristal de composto de pirimidina
AU2021309779A1 (en) * 2020-07-15 2023-02-23 Taiho Pharmaceutical Co., Ltd. EGFR inhibitor
KR20230031926A (ko) 2020-07-15 2023-03-07 다이호야쿠힌고교 가부시키가이샤 종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합
CA3199714A1 (fr) * 2020-11-20 2022-05-27 Isao Miyazaki Agent therapeutique antitumoral a migration cerebrale contenant un compose pyrimidine fusionne en tant que principe actif
AU2022282261A1 (en) * 2021-05-24 2023-12-21 Taiho Pharmaceutical Co., Ltd. Treatment methods for subjects with cancer having an aberration in egfr and/or her2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2013118817A1 (fr) * 2012-02-07 2013-08-15 大鵬薬品工業株式会社 Composé de quinolyl pyrrolopyrimidine ou son sel
JP6035423B2 (ja) * 2013-08-12 2016-11-30 大鵬薬品工業株式会社 新規な縮合ピリミジン化合物又はその塩
PL3345907T3 (pl) * 2015-09-01 2020-09-07 Taiho Pharmaceutical Co., Ltd. Związki pirazolo[3,4-d]pirymidynowe lub ich sole
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
AU2017222908B2 (en) 2016-02-23 2021-02-04 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
CA3021324A1 (fr) 2016-04-19 2017-10-26 The Regents Of The University Of California Inhibiteurs de erbb et leurs utilisations
JP6779835B2 (ja) 2017-06-15 2020-11-04 株式会社日立製作所 監視制御システム、監視制御装置及び監視制御方法

Also Published As

Publication number Publication date
EP3909584A1 (fr) 2021-11-17
US11078207B2 (en) 2021-08-03
CA3121722A1 (fr) 2020-07-16
SG11202107528PA (en) 2021-08-30
US20210024530A1 (en) 2021-01-28
TW202043230A (zh) 2020-12-01
DK3909584T3 (da) 2024-01-15
KR102640463B1 (ko) 2024-02-23
TWI783204B (zh) 2022-11-11
BR112021013460A2 (pt) 2021-09-21
JP6783974B1 (ja) 2020-11-11
FI3909584T3 (fi) 2024-01-09
AU2020206640B2 (en) 2022-09-08
PT3909584T (pt) 2024-01-12
EP3909584B1 (fr) 2023-12-13
CN113271950B (zh) 2024-04-30
KR20210102373A (ko) 2021-08-19
MX2021008252A (es) 2021-08-16
CN113271950A (zh) 2021-08-17
JPWO2020145374A1 (ja) 2021-02-18
MA54702A (fr) 2021-11-17
ES2969151T3 (es) 2024-05-16
EP3909584A4 (fr) 2022-09-28
AU2020206640A1 (en) 2021-08-12
WO2020145374A1 (fr) 2020-07-16
PL3909584T3 (pl) 2024-03-25

Similar Documents

Publication Publication Date Title
CA3121722C (fr) Compose pyrimidine ou sel correspondant
CN106029659B (zh) 谷氨酰胺酶抑制剂
KR101414931B1 (ko) 아실티오우레아 화합물 또는 그 염 및 그 용도
US8436011B2 (en) Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof
AU2021261899A1 (en) Pyridine compound
CN105566321B (zh) 杂芳化合物及其在药物中的应用
JP2016169161A (ja) 新規イミダゾピリジン化合物
EP4197538A1 (fr) Inhibiteur du récepteur du facteur de croissance épidermique
KR101905295B1 (ko) 나프티리딘디온 유도체
WO2015189433A1 (fr) Pyridazinones pour le traitement du cancer
EP4183395A1 (fr) Combinaison contenant un composé pyrimidine destinée à être utilisée dans le traitement de tumeurs
JP7495983B2 (ja) Ｅｇｆｒ阻害剤
RU2817044C1 (ru) Ингибитор egfr
RU2787992C1 (ru) Пиримидиновое соединение или его соль
US10807959B2 (en) WDR5-MLL1 inhibitors and modulators
KR20220015433A (ko) 피롤로피리미딘 골격을 갖는 신규한 카보네이트 화합물 또는 그 약학적으로 허용 가능한 염
AU2021307245A1 (en) Crystal of pyrimidine compound

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601

EEER Examination request

Effective date: 20210601